In fact, some mutations in SF3B1, U2AF35 and SRSF2 have been demonstrated to affect alternative splicing [38,40,44,45,46,47,48,49,50,51,52], and SF3B1 and SRSF2 mutations are suggested to be adverse prognostic risks of CLL and of MDS, respectively [43,53,54,55,56]. Here, SRSF2 is linked to myelodysplastic syndrome.